AlphaCrest Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-73,504
| Closed | -$2.49M | – | 1008 |
|
|
2022
Q3 | $2.49M | Buy |
73,504
+23,962
| +48% | +$811K | 0.15% | 152 |
|
|
2022
Q2 | $1.43M | Buy |
+49,542
| New | +$1.43M | 0.07% | 497 |
|
|
2022
Q1 | – | Sell |
-32,459
| Closed | -$947K | – | 1404 |
|
|
2021
Q4 | $947K | Buy |
32,459
+2,229
| +7% | +$65K | 0.04% | 821 |
|
|
2021
Q3 | $806K | Buy |
30,230
+6,115
| +25% | +$163K | 0.04% | 705 |
|
|
2021
Q2 | $743K | Sell |
24,115
-1,139
| -5% | -$35.1K | 0.03% | 793 |
|
|
2021
Q1 | $661K | Buy |
25,254
+6,729
| +36% | +$176K | 0.04% | 669 |
|
|
2020
Q4 | $466K | Sell |
18,525
-8,396
| -31% | -$211K | 0.04% | 686 |
|
|
2020
Q3 | $561K | Buy |
+26,921
| New | +$561K | 0.06% | 527 |
|
|
2020
Q2 | – | Sell |
-37,650
| Closed | -$677K | – | 1108 |
|
|
2020
Q1 | $677K | Buy |
37,650
+26,894
| +250% | +$484K | 0.08% | 437 |
|
|
2019
Q4 | $255K | Sell |
10,756
-19,944
| -65% | -$473K | 0.02% | 1141 |
|
|
2019
Q3 | $844K | Buy |
30,700
+16,800
| +121% | +$462K | 0.05% | 661 |
|
|
2019
Q2 | $460K | Sell |
13,900
-9,500
| -41% | -$314K | 0.04% | 724 |
|
|
2019
Q1 | $820K | Buy |
23,400
+8,900
| +61% | +$312K | 0.12% | 263 |
|
|
2018
Q4 | $482K | Buy |
+14,500
| New | +$482K | 0.14% | 256 |
|